The Effects of Adding Dexamethasone in the Quadratus Lumborum Block

Comparing the Effects of Adding Dexamethasone in 0.25% Ropivacaine With 0.5% Ropivacaine Alone in the Quadratus Lumborum Block

The quadratus lumborum block is widely used in abdominal surgery for post-operative analgesia. It is now also used for pain relief after hip surgery. Under the traditional blocking method, a high concentration of long-acting local anesthetic is used in order to achieve a long-term blocking effect. However, this is also likely to cause the patient's quadriceps weakness during the block period, increasing the risk of the patient falling during rehabilitation. It also increases systemic local anesthetic poisoning and may even trigger the risk of serious side effects such as cardiac arrest. Ropivacaine is a novel long-acting topical amine anesthetics that lasts long and has anesthetic and analgesic effects. Its pharmacological characteristics are low cardiotoxicity, sensory block and motor block separation at low concentrations more obvious, and with the external peripheral vasoconstriction. Therefore, the drug is especially suitable for postoperative analgesia.

Dexamethasone is a synthetic corticosteroid for the treatment of a wide range of symptoms including rheumatic diseases, certain skin diseases, severe allergies, asthma, chronic obstructive pulmonary disease, cerebral edema, and may also be combined with antibiotics for tuberculosis patients. It is becoming more common to use steroids as an adjuvant to local anesthetics in peripheral nerve block. Steroids have neurological blockade effects by blocking the nociceptive transmission of pith-type C-fibers and inhibiting the release of ectopic neurons. Dexamethasone, as a local anesthetic adjuvant in peripheral nerve block, has also been widely studied recently.

In order to reduce the incidence of long-acting topical anesthetics from the nerve block in the quadratus lumborum block, reducing the local anesthetic concentration is a feasible method. However, this will also result in a shorter time to neurological block. The investigators hypothesized that the addition of Dexamethasone 5 mg to low concentrations (0.25%) of Ropivacaine would prolong postoperative analgesia. Therefore, the purpose of this study was to compare the postoperative analgesia and the side effects of postoperative quadratus lumborum block with the addition of Dexamethasone 4mg to Ropivacaine (0.25%) in low concentrations and Ropivacaine (0.5%) alone.

Study Overview

• Status: Not yet recruiting
• Conditions: Analgesia; Motor Activity
• Intervention / Treatment: Procedure: Quadratus Lumborum block

Detailed Description

Test drug:

1. Name: Dexamethasone sod. Phosphate
2. Dosage form: 5 milligram (mg)/1 milliliter (mL)/Amp
3. Dose(s): 4mg
4. Dosing schedule: Dexamethasone 4mg adds into 0.25% Ropivacaine 20 mL
5. Mechanism of action: Synthesis of adrenocortical hormones, has a strong anti-inflammatory effect, can prolong the effect of local anesthetic drugs
6. Pharmacological category: HS051 Glucocorticoids

Study design:

1. ☑ Control: ☑ placebo（N/S 0.8 mL + 0.25% Ropivacaine 20 mL）

• active (Dexamethasone 4mg＋0.25% Ropivacaine 20 mL)

• others（N/S 0.8 mL + 0. 5% Ropivacaine 20 mL） □ Uncontrolled 2. Blinding: □ open-label □ single blind ☑ double blind □ others 3. Randomized: ☑ yes □ no 4. ☑ Parallel □ cross-over □ others 5. Duration of study：from Institutional Review Board (IRB) approval ~to 12, 31, 2022 ,total 24 months Duration of Enrollment : from IRB approval ~to 12, 31, 2022 ,total 24 months Duration of treatment：from IRB approval ~to 12, 31, 2022 ,total 24 months Duration of follow-up: from IRB approval ~to 12, 31, 2022 ,total 24 months

  • Multi-national □multi-center(Taiwan) ☑single center(Taiwan) 6. Number of subjects: 90 7. Is there any of the followings included Data Safety and Monitoring Board (DSMB)
  • yes ☑ no

Assessment criteria:

1. Efficacy:

1. The intensity of pain was assessed using a 0 to 10 Numerical Rating Scale (NRS) to quantify their degree of pain; where 0 means no pain and 10 the worst pain imaginable.
2. The analgesic activity was assessed using standard measures during the 48-hour treatment period: baseline pain intensity, time to rescue medication, and overall patient evaluation of study medication.

2. Safety:

1. Record the hemodynamic parameters during the 60-minute observation period in the anesthesia recovery room.
2. The severity of postoperative side effects (nausea, vomiting, pruritus) was quantified using different scales. Other side effects, including dizziness and drowsiness, are also recorded.
3. Motor block is assessed using Modified Bromage Scale.

3. Pharmacokinetics: None

4. Quality of life:

1. analgesic activity and duration of action
2. patient satisfaction

• Study Type: Interventional
• Enrollment (Anticipated): 90
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Hung-Te Hsu, MD, PhD; Phone Number: 7033 +88673121101; Email: hdhsu1228@hotmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• American Society of Anesthesiologists (ASA) classification: I ~ III
• Patients who received quadratus lumborum block for post-hip surgery analgesia

Exclusion Criteria:

• Lumbar plexus degeneration,
• Coagulation abnormalities with international normalized ratio (INR) > 1.5
• Obvious heart, lung, liver or kidney disease
• Body mass index less than 18.5 or greater than 35
• Pregnancy
• Regular use of steroids or opiates Opioids
• Chronic medication or alcohol abuse
• Previous allergies or adverse reactions to opiates, dexamethasone, or ropivacaine

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group lower dose ropivacaine with dexamethasone; Quadratus lumborum block was administered with 0.25% Ropivacaine 20 ml + dexamethasone 0.8 ml (4mg) at the end of surgery	Procedure: Quadratus Lumborum block; Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.
Active Comparator: Group higher dose ropivacaine with N/S; Quadratus lumborum block was administered with 0.5% Ropivacaine 20 ml + N/S 0.8 ml at the end of surgery	Procedure: Quadratus Lumborum block; Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.
Placebo Comparator: Group lower dose ropivacaine with N/S; Quadratus lumborum block was administered with 0.25% Ropivacaine 20 ml + N/S 0.8 ml at the end of surgery	Procedure: Quadratus Lumborum block; Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the post-operative analgesic effect of quadratus lumborum block	The pain will be assessed using a 0 to 10 Numerical Rating Scale (NRS); In an hour in the recovery room, the pain will be evaluated every 15 minutes.; Then the pain will be assessed at the 3rd, 6th, 12th, 24th, 36th, and 48th hours after surgery.	Within 48 hours after surgery

Collaborators and Investigators

• Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
• Investigators: Principal Investigator: Hung-Te Hsu, MD, PhD, Department of Anesthesiology, Kaohsiung Medical University Hospital

Study record dates

Study Major Dates

• Study Start (Anticipated): July 31, 2020
• Primary Completion (Anticipated): December 31, 2022
• Study Completion (Anticipated): December 31, 2022

Study Registration Dates

• First Submitted: July 27, 2020
• First Submitted That Met QC Criteria: July 30, 2020
• First Posted (Actual): August 3, 2020

Study Record Updates

• Last Update Posted (Actual): August 4, 2020
• Last Update Submitted That Met QC Criteria: August 2, 2020
• Last Verified: June 1, 2020

More Information

Terms related to this study

• Other Study ID Numbers: KMUHIRB-F(I)-20200099

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No